Recent News

Early Research Findings on Novel Bispecific Monoclonal Antibody in Resistant Myeloma

Racial/Ethnic Differences in Patients With Myeloma: Clonal Hematopoiesis, Tumor Markers, and Outcomes

Phase III GMMG-HD7 Trial: Isatuximab-Based Therapy for Newly Diagnosed Myeloma

Activating T Cells With Talquetamab to Treat Multiple Myeloma

Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma

First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma

ASH 2021: Novel BCMA-Targeting Bispecific Antibody Under Study in Resistant Myeloma

ASH 2021: Bispecific Antibody Teclistamab in Early-Phase Myeloma Study

ASH 2021: Novel Immunocytokine Under Study in Resistant Multiple Myeloma

ASH 2021: Early-Phase Trial of Idecabtagene Vicleucel in Resistant Multiple Myeloma

ASH 2021: Combination Iberdomide and Dexamethasone for Resistant Multiple Myeloma

FDA Approves Daratumumab Combination Therapy for Multiple Myeloma

Is Induction With Lenalidomide-Based Therapy Plus Tandem ASCT of Benefit in Multihit Myeloma?

SITC 2021: Engineered Toxin Body Under Study in Resistant Multiple Myeloma

Novel Antibody-Drug Conjugate Under Study in Combination Therapy for Resistant Myeloma

Front-Line Daratumumab Triplet: Updated Overall Survival Results From MAIA

Can Adding E-Selectin Antagonist to Chemotherapy Improve Outcomes in AML?

Can a Novel Triplet Regimen Prevent Disease Progression in Patients With High-Risk Smoldering Myeloma?

Is There a Role for Consolidation Treatment in Newly Diagnosed Patients With Multiple Myeloma?

ASTRO 2021: Use of Radiotherapy in Palliation of Multiple Myeloma Bone Lesions

Melphalan Flufenamide Is Withdrawn as Myeloma Treatment From U.S Markets

Early and Late Relapse in Myeloma: Navigating the Complex Treatment Waters

Long-Term Strategy Required for Newly Diagnosed Multiple Myeloma

Is the COVID-19 mRNA Vaccine Effective in Patients With Multiple Myeloma?

Chemotherapy for Newly Diagnosed Myeloma in Low-Income Setting: Long-Term Findings

COVID-19 and Multiple Myeloma: Patient Questionnaire Findings From the UK

Salvage Autologous HSCT for Relapsed Myeloma: From the Polish Myeloma Study Group

SOHO 2021: Preclinical Look at Myeloma Cell Viability With Metformin Plus Lenalidomide

SOHO 2021: Does Prolonged Lenalidomide Maintenance Improve Survival After Transplant in Myeloma?

SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma

Bone-Directed Therapy in Myeloma: How Often Should Bisphosphonates Be Given?

COVID-19 and Novel Agents for Myeloma: From a Single Center in the Czech Republic

Relapse-Associated Genetic Alterations and Drug-Specific Resistance in Myeloma

FDA Brief: Orphan Drug Designation for Two Novel Multiple Myeloma Treatments

COVID-19 Vaccine Responses Among Patients With Multiple Myeloma

Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma

ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma

BOSTON Trial: Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma

Trends in Multiple Myeloma–Related Inpatient Mortality

Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma?

Comparing Two Oral Doublet Regimens for Resistant Multiple Myeloma

FDA Issues Safety Alert for Use of Melphalan Flufenamide in Multiple Myeloma

Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma